Announcements Trials
Browse Landscape

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Genitourinary 7Thoracic 3Tumor-Agnostic 2Breast 2Sarcoma 1Plasma cell 1Other 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urine Specimen Collection × Breast × Clear all
NCT04268693 2022-11-17

EDC-TNBC

George Washington University

Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT00235235 2015-12-09

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Hoosier Cancer Research Network

Terminated
80 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡